Upgrade to SI Premium - Free Trial

Incyte (INCY) Reiterated at Buy by Stifel After FDA Response to sBLA Submission

March 9, 2026 8:00 AM
Stifel analyst Stephen Willey reiterated a Buy rating and $120.00 price target on Incyte (NASDAQ: INCY).The analyst commented, "FDA’s issuance ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments